Application of trilobatin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease

A technology for non-alcoholic fatty liver disease, which is applied in the application field of preparing drugs for preventing and/or treating non-alcoholic fatty liver disease, and can solve the problems that there is no relevant research on the effect.

Inactive Publication Date: 2021-07-16
GUANGDONG PHARMA UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented research suggests how tetrahydroguanolone can be used effectively against alcohols called nonshealthy fats or bad chlorides from drinking water without affecting their ability to lower body weight by reducing excessive calorie intake compared with regular foods like sugar.

Problems solved by technology

The technical problem addressed in this patents relates to finding effective drugs or agents able to reduce excessive accumulations associated with metabolism abnormalities such as hypertension, heart diseases like cardiovascular events, cholesteremia, fibrotic changes, cancer, chronic renal failures, acute kidney stones, biliary obstruction, congestive symptoms, cerebrum malaria, multiple organ system involvement, among others.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trilobatin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease
  • Application of trilobatin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease
  • Application of trilobatin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 3

[0050] Example 1 Effect of Trilobatin on Glucose Metabolism in Nonalcoholic Fatty Liver Mice

[0051] 1. Experimental method

[0052] Immediately after the end of the experiment, the blood was drawn from the heart, and sodium heparin was added for anticoagulation. After the collected blood was left for 30 minutes, it was centrifuged at 4000rpm / min for 10 minutes, and the supernatant was collected and packed into EP tubes, and stored in a -80°C refrigerator.

[0053] Plasma was taken, and fasting blood glucose (Glu) and fructosamine (Fru) were detected using an automatic biochemical analyzer.

[0054] 2. Experimental results

[0055] Glucose metabolism results such as figure 1 As shown, compared with the normal group, Glu and Fru of the mice in the model group were significantly increased (Pfigure 1 -A, Pfigure 1 -B, P<0.05). The results showed that trilobatin could improve blood glucose metabolism disorder in non-alcoholic fatty liver mice.

Embodiment 2 3

[0056] Example 2 Effect of Trilobatin on Lipid Metabolism in Nonalcoholic Fatty Liver Mice

[0057] 1. Experimental method

[0058] Plasma was collected, and the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were detected using an automatic biochemical analyzer.

[0059] 2. Experimental results

[0060] Lipid metabolism results such as figure 2 As shown, compared with the normal group, the TC, LDL-C, and HDL-C contents of the mice in the model group were all significantly increased ( figure 2 -B, figure 2 -C, figure 2 -D, P figure 2 -A, P>0.05); compared with the model group, the trilobatin low and high dose groups could significantly reduce the contents of TC, LDL-C and HDL-C in mouse plasma ( figure 2 -B, figure 2 -C, figure 2 -D, P figure 2 -A, P<0.05, P<0.01), the results show that trilobatin can improve the abnormal blood lipid metabolism in non-alcoholic fat...

Embodiment 3 3

[0061] Example 3 Effect of trilobatin on liver tissue ALT and AST of nonalcoholic fatty liver mice

[0062] 1. Experimental method

[0063] Plasma was taken, and the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the plasma were detected using an automatic biochemical analyzer.

[0064] 2. Experimental results

[0065] Transaminases are involved in the whole process of the liver, and an important sign of liver problems is elevated transaminases. ALT mainly exists in the liver cytoplasm, and AST mainly exists in the mitochondria of liver cells. The two most sensitive enzymes of liver cells are ALT and AST. When the liver cells are damaged, the activities of ALT and AST increase, which can reflect the damage of liver cells. degree of size. The result is as image 3 As shown, compared with the blank group, the levels of ALT and AST in the liver tissue of the mice in the model group were significantly increased ( image 3 -A, image 3 -B...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of trilobatin in preparation of a medicine for preventing and/or treating non-alcoholic fatty liver disease. The trilobatin is researched and found for the first time to be capable of improving blood glucose metabolism disorder, abnormal blood lipid metabolism, liver function impairment, liver inflammatory response, liver injury, liver fatty degeneration and lipid deposition caused by the non-alcoholic fatty liver disease, and the trilobatin and the derivative thereof have a good treatment effect on the non-alcoholic fatty liver disease. The invention provides a novel and efficient natural medicine source for treating the non-alcoholic fatty liver disease.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap